Clinical Trial Detail

NCT ID NCT02555657
Title Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Merck Sharp & Dohme Corp.
Indications

triple-receptor negative breast cancer

Therapies

Pembrolizumab

Eribulin

Gemcitabine

Vinorelbine

Capecitabine

Age Groups: adult

Additional content available in CKB BOOST